Search Within

Jedd D Wolchok

Formats
  1. Journal Article (450)
  2. Meeting Abstract (414)
  3. Book Section (19)
  4. Editorial (9)
  5. Review (5)
  6. Correspondence (3)
  7. Research Letter (3)
  8. Book Whole (1)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (905)
  2. GSK Faculty (905)
  3. Melanoma and Immunotherapeutics Service (905)
  4. Solid Tumor Oncology Division (905)
  5. Melanoma Disease Management Team (222)
  6. Sloan Kettering Institute Postdocs (195)

More Groups

People
  1. Taha Merghoub (230)
  2. Michael Postow (158)
  3. Alan Houghton (118)
  4. Margaret Callahan (113)
  5. Paul Chapman (107)
  6. Katherine Panageas (92)

More People

Years
  1. 2024 (2)
  2. 2023 (15)
  3. 2022 (46)
  4. 2021 (42)
  5. 2020 (46)
  6. 2019 (47)

More Years

Publications
  1. Journal of Clinical Oncology (171)
  2. Journal for ImmunoTherapy of Cancer (81)
  3. Cancer Research (59)
  4. Clinical Cancer Research (35)
  5. Annals of Oncology (34)
  6. European Journal of Cancer (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (171)
  2. American Association for Cancer Research (130)
  3. Biomed Central Ltd (83)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (52)
  6. Oxford University Press (44)

More Publishers

Results (905)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacologic inhibition of the glycolytic pathway improves response to immune checkpoint blockade
    Meeting Abstract

    Verma, S.; Serganova, I.; Budhu, S.; Dong, L.; Ko, M.; Mangarin, L.; Merghoub, T.; Wolchok, J.; Zappasodi, R.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • APR-246 enhances tumor immunogenicity even in the absence of p53
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Liu, C.; Budhu, S.; George, M. M.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J. D.; Merghoub, T.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Combining a novel MEK inhibitor with immunomodulation to promote an anti-tumor response
    Meeting Abstract

    Dong, L.; Choi, H.; Budhu, S.; Schulze, I.; Verma, S.; Mehanna, N.; Rosen, N.; Merghoub, T.; Wolchok, J.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model
    Meeting Abstract

    George, M. M.; Warner, A. B.; Hamadene, L.; Hirschhorn, D.; Houghton, A. N.; Wolchok, J. D.; Merghoub, T.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy
    Meeting Abstract

    Ghosh, A.; Michel, J.; Venkatesh, D.; Mezzadra, R.; Dong, L.; Samaan, F.; Gomez, R.; Suek, N.; Holland, A.; Ho, Y. J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)
    Meeting Abstract

    Jensen, R. E.; Zheng, Y.; Atkins, M. B.; Chmielowski, B.; Tarhini, A. A.; Truong, T. G.; Davar, D.; O'Rourke, M. A.; Curti, B. D.; Brell, J. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Lewis, K. D.; Grob, J. J.; Rutkowski, P.; Lao, C. D.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192
    Meeting Abstract

    Gibney, G. T.; Lee, S. J.; Atkins, M. B.; Wong, T. Z.; Guerriero, J.; Marron, T. U.; Cohen, G. I.; Truong, T. G.; Carvajal, R. D.; Snyder, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs)
    Meeting Abstract

    Gainor, J. F.; Ravi, A.; Awad, M. M.; Holton, M.; Arniella, M.; Stewart, C.; Freeman, S.; Leshchiner, I.; Chow, A.; Henick, B. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma
    Meeting Abstract

    Balachandran, V. P.; Rojas, L. A.; Sethna, Z.; Soares, K.; Derhovanessian, E.; Mueller, F.; Yadav, M.; Basturk, O.; Gonen, M.; Wei, A. C. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save